Clinical Applications
Peer-reviewed research has explored GcMAF across a broad spectrum of immune-related conditions. Select a category below to review the evidence, mechanism, and clinical considerations.
The Nagalase Connection
A common thread across the conditions explored below is the role of nagalase — an enzyme secreted by viruses, bacteria, and tumour cells that deglycosylates GcProtein, preventing the endogenous production of GcMAF and effectively disabling macrophage-mediated immunity. By measuring serum nagalase levels, clinicians can assess the degree of immune suppression and monitor the efficacy of GcMAF intervention over time.
Cancer Care
Activating macrophage-mediated tumour surveillance
Research suggests GcMAF may activate macrophages to target and eliminate malignant cells, potentially offering complementary support to conventional oncology protocols.
Neurological Disorders
Supporting microglial activation and neuroinflammatory balance
Emerging research explores GcMAF's potential role in supporting neurological health, particularly through its interaction with brain-resident macrophages known as microglia.
Autoimmune Diseases
Rebalancing immune dysregulation at its source
In autoimmune conditions, research suggests GcMAF may help recalibrate immune function — not by suppressing the system, but by restoring appropriate regulatory balance.
Chronic Infections
Restoring macrophage-mediated pathogen clearance
Chronic infections often persist because of a suppressed or dysregulated immune response. Research indicates GcMAF may help restore the immune capacity needed for effective pathogen elimination.
Immune Enhancement
Optimising immune readiness in healthy and at-risk individuals
Beyond disease management, GcMAF is explored for its potential to enhance baseline immune function, resilience, and overall physiological vitality.